移至主內容

Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease

亦提供以下語言

背景

Long-term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor impairments and only minimally increasing dopaminergic adverse events.

目的

To compare the efficacy and safety of adjunct lisuride therapy versus bromocriptine in patients with Parkinson's disease, already established on levodopa and suffering the long-term complications of therapy.

搜尋策略

Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories, Roche Products Limited and Sandoz Limited.

選擇標準

Randomised controlled trials of lisuride versus bromocriptine in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.

資料收集與分析

Data was abstracted independently by each author and differences settled by discussion.

主要結果

Only one randomised cross-over trial including 20 patients has compared lisuride with bromocriptine as adjunct therapy in Parkinson's disease. Both lisuride and bromocriptine improved motor fluctuations with no significant differences between the agonists. However, this conclusion is based on an unvalidated 4 point rating scale which could only record positive outcomes. This, combined with the small size of the trial, suggests that firm conclusions on motor fluctuations should not be drawn. Lisuride and bromocriptine produced similar benefits in parkinsonian impairments according to the Columbia Rating Scale. Adverse events were similar with the two agonists and no withdrawals were reported from either drug.

作者結論

The small size of this study and other methodological problems do not allow any firm conclusions to be drawn regarding the efficacy and safety of lisuride compared with bromocriptine in advanced Parkinson's disease with motor complications.

引用文獻
Clarke C E, Speller J M, Clarke CE. Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database of Systematic Reviews 1999, Issue 2. Art. No.: CD001514. DOI: 10.1002/14651858.CD001514.

我們對Cookie的使用

我們使用必要的 cookie 使我們的網站正常運作。我們還希望設置可選擇分析的 cookie,以幫助我們進行改進網站。除非您啟用它們,否則我們不會設置可選擇的 cookie。使用此工具將在您的設備上設置 cookie,以記住您的偏好。您隨時可以隨時通過點擊每個頁面下方的「Cookies 設置」連結來更改 Cookie 偏好。
有關我們使用 cookie 的更多詳細資訊,請參閱我們的 cookie 頁面

接受所有
配置